Korea Arlico Pharm
알리코제약 · 260660
Health Care Pharmaceuticals · KOSDAQ
Market cap US$29.8M (₩41.1B)
Overview
Korea Arlico Pharm makes prescription and over-the-counter medicines, tablets, capsules, and other drug formulations, used by patients and dispensed through hospitals and pharmacies in South Korea and exported abroad.
Listed on KOSDAQ, South Korea's small-cap board, it supplies domestic healthcare channels, provides contract manufacturing (producing medicines on behalf of other pharmaceutical companies), and exports finished drugs and health-related products overseas. Its business spans four main lines: domestic drug sales, contract manufacturing, international exports, and medical devices alongside health-functional foods and cosmetics.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$135.6M
- FY2024US$138M
- FY2025US$145.8M
Operating profit
- FY2023US$2.2M
- FY2024−US$3.7M
- FY2025US$716.8K
Net income
- FY2023US$2.2M
- FY2024−US$3.9M
- FY2025−US$438.7K
Key ratios (FY2025)
Why it matters
The company operates its own central research laboratory, relocated and expanded to Gwangyo, focused on developing improved new drugs and differentiated drug formulations.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?